

2015 Regular Session

HOUSE BILL NO. 72

BY REPRESENTATIVE MACK AND SENATOR THOMPSON

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(F)(12) through (28) and to enact R.S.
3 40:964(Schedule I)(C)(60) through (63) and (E)(10) and (11) and R.S. 40:989.1(F)
4 and 989.2(F), relative to the Uniform Controlled Dangerous Substances Law; to add
5 certain substances to Schedule I of the Uniform Controlled Dangerous Substances
6 Law; to amend provisions of law regarding synthetic cannabinoids; to provide for
7 exceptions for certain dietary supplements; and to provide for related matters.

8 Be it enacted by the Legislature of Louisiana:

9 Section 1. R.S. 40:964(Schedule I)(F)(12) through (28) are hereby amended and
10 reenacted and R.S. 40:964(Schedule I)(C)(60) through (63) and (E)(10) and (11) and R.S.
11 40:989.1(F) and 989.2(F) are hereby enacted to read as follows:

12 §964. Composition of schedules

13 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.
14 40:962, consist of the following drugs or other substances, by whatever official
15 name, common or usual name, chemical name, or brand name designated:

16 SCHEDULE I

17 * * *

18 C. Hallucinogenic substances. Unless specifically excepted or unless listed
19 in another schedule, any material, compound, mixture, or preparation, which
20 contains any quantity of the following hallucinogenic substances, or which contains
21 any of their salts, isomers, or salts of isomers, whenever the existence of such salts,
22 isomers, or salts of isomers is possible within the specific chemical designation, for

1 purposes of this Paragraph only, the term "isomer" includes the optical, position, and
 2 geometric isomers:

3 * * *

4 (60) 4-bromo-2,5-dimethoxyphenethylamine (2C-B)

5 (61) N-(2-methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine
 6 (25B-NBOMe)

7 (62) 5-(2-methylaminopropyl)benzofuran (5-MAPB)

8 (63) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-Hydroxy-MIPT)

9 * * *

10 E. Stimulants. Unless specifically excepted, or contained within a
 11 pharmaceutical product approved by the United States Federal Food and Drug
 12 Administration, or unless listed in another schedule, any material, compound,
 13 mixture, or preparation which contains any quantity of the following substances
 14 having a stimulant effect on the central nervous system including its salts, isomers,
 15 esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such
 16 salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible
 17 within the specific chemical designation:

18 * * *

19 (10) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one (Alpha-PBT)

20 (11) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (Alpha-PVT)

21 F. Synthetic cannabinoids. Unless specifically excepted, or contained within
 22 a pharmaceutical product approved by the United States Food and Drug
 23 Administration, or unless listed in another schedule, any material, compound,
 24 mixture, or preparation, which contains any quantity of a synthetic cannabinoid
 25 found to be in any of the following individual compounds or chemical groups, or any
 26 of those individual compounds or groups which contain any synthetic cannabinoid
 27 salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the
 28 existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs
 29 is possible within the specific compounds or chemical groups:

30 * * *

1 (12) Naphthylamidindoles: any compound containing a N-(naphthyl)-1H-
 2 indole-3-carboxamide structure, whether or not further substituted in the indole ring
 3 to any extent or whether or not substituted in the naphthyl ring to any extent.

4 (13) Quinolinyndolecarboxylates: any compound containing a
 5 quinolin-8-yl-1H-indole-3-carboxylate or isoquinolin-8-yl-1H-indole-3-carboxylate
 6 structure, whether or not further substituted in the indole, ring to any extent or the
 7 quinoline, or isoquinoline ring to any extent.

8 (14) Adamantylamidindoles: Any compound containing a
 9 N-(adamantyl)-1H-indole-3-carboxamide structure, whether or not further
 10 substituted in the indole ring to any extent or whether or not substituted in the
 11 adamantyl ring to any extent.

12 ~~(15) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-H-~~
 13 ~~indazole-3-carboxamide~~

14 ~~(16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1-H-indole-3-~~
 15 ~~carboxamide~~

16 ~~(17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-~~
 17 ~~carboxamide~~

18 ~~(18)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-~~
 19 ~~3-carboxamide~~

20 ~~(19)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carbo~~
 21 ~~xamide~~

22 (15) Naphthylindolecarboxylates: Any compound containing a
 23 naphthyl-1H-indole-3-carboxylate structure, whether or not further substituted in the
 24 indole ring or the naphthyl ring to any extent.

25 (16) Benzylindolecarboxamides: Any compound containing a
 26 N-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted in
 27 the indole ring or the phenyl ring to any extent.

28 (17) Quinolinyndolecarboxamides: Any compound containing a
 29 N - q u i n o l i n y l - 1 H - i n d o l e - 3 - c a r b o x a m i d e o r

1 N-isoquinoliny-1H-indole-3-carboxamide structure, whether or not further
 2 substituted in the indole, quinoline or the isoquinoline ring to any extent.

3 (18) Phenylindolecarboxamides: Any compound containing a
 4 N-phenyl-1H-indole-3-carboxamide structure, whether or not further substituted in
 5 the indole ring or the phenyl ring to any extent.

6 (19) Butaldehydeamidoindoles: Any compound containing a
 7 N-(1-oxobutan-2yl)-1H-indole-3-carboxamide structure, with or without substitution
 8 in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide,
 9 alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic
 10 alcohol, hydroxyl, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl
 11 or a tetrahydropyranylmethyl group, whether or not further substituted on the
 12 butaldehyde group to any extent.

13 (20) Phenylpropionaldehydeamidoindoles: Any compound containing a
 14 N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without
 15 substitution in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
 16 halide, alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl,
 17 aliphatic alcohol, hydroxyl, morpholinoethyl, alkylmorpholinomethyl,
 18 alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further
 19 substituted on the phenylpropionaldehyde group to any extent.

20 (21) Cumylindolecarboxamides: Any compound containing a
 21 N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without
 22 substitution in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
 23 halide, alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl,
 24 aliphatic alcohol, hydroxyl, morpholinoethyl, alkylmorpholinomethyl,
 25 alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further
 26 substituted on the phenyl group to any extent.

27 ~~(20)~~(22) (1-(5-fluoropentyl)-1H-benzimidazol-2-yl)(naphthalen-1-yl)
 28 methanone

29 ~~(21)~~(23) (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) methanone

30 ~~(22)~~ Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate

1 F. The provisions of this Section shall not apply to any dosage form which
 2 is labeled as a dietary supplement and is manufactured in compliance with the
 3 requirements of sections 402(g)(2), 415 and 761 of the Federal Food, Drug and
 4 Cosmetic Act (21 USC 342(g)(2), 350d, 379aa-1).

5 Section 2. This Act shall become effective upon signature by the governor or, if not
 6 signed by the governor, upon expiration of the time for bills to become law without signature
 7 by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If
 8 vetoed by the governor and subsequently approved by the legislature, this Act shall become
 9 effective on the day following such approval.

 SPEAKER OF THE HOUSE OF REPRESENTATIVES

 PRESIDENT OF THE SENATE

 GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____